George Lemaitre Sells 150,000 Shares of LeMaitre Vascular (NASDAQ:LMAT) Stock

LeMaitre Vascular, Inc. (NASDAQ:LMAT) CEO George Lemaitre sold 150,000 shares of LeMaitre Vascular stock in a transaction dated Thursday, February 26th. The stock was sold at an average price of $106.76, for a total transaction of $16,014,000.00. Following the transaction, the chief executive officer directly owned 1,532,304 shares of the company’s stock, valued at approximately $163,588,775.04. This represents a 8.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

LeMaitre Vascular Stock Up 0.4%

Shares of NASDAQ LMAT opened at $107.85 on Wednesday. LeMaitre Vascular, Inc. has a 1 year low of $71.42 and a 1 year high of $115.33. The firm has a 50-day simple moving average of $87.95 and a two-hundred day simple moving average of $88.48. The company has a market cap of $2.46 billion, a P/E ratio of 42.97, a PEG ratio of 2.01 and a beta of 0.66. The company has a debt-to-equity ratio of 0.43, a current ratio of 12.89 and a quick ratio of 10.95.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings results on Wednesday, February 25th. The medical instruments supplier reported $0.68 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.01. LeMaitre Vascular had a return on equity of 14.72% and a net margin of 23.13%.The firm had revenue of $64.45 million for the quarter, compared to the consensus estimate of $62.98 million. During the same period in the prior year, the business posted $0.49 earnings per share. The company’s revenue for the quarter was up 15.7% on a year-over-year basis. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. Research analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 26th. Stockholders of record on Thursday, March 12th will be issued a $0.25 dividend. The ex-dividend date is Thursday, March 12th. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.20. This represents a $1.00 dividend on an annualized basis and a dividend yield of 0.9%. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 31.87%.

Trending Headlines about LeMaitre Vascular

Here are the key news stories impacting LeMaitre Vascular this week:

• Positive Sentiment: Company announced a dividend increase (quarterly dividend raised to $0.25) and a share buyback program, a catalyst that lifted investor sentiment and helped drive the rally. Read More.
• Positive Sentiment: Analyst support has improved — at least one firm raised its price target to $118 and other shop upgrades/positive notes add buy-side conviction around the stock. Read More.
• Positive Sentiment: Technical picture is constructive after a recent “golden cross” (50‑day MA crossing above 200‑day), which can attract momentum and technical buying. Read More.
• Neutral Sentiment: Recent quarterly results beat consensus (EPS and revenue) and management set FY2026 guidance (EPS 2.81–3.01), which provides useful context for longer-term holders but is already baked into current momentum. Read More.
• Negative Sentiment: Significant insider selling was reported recently — including CEO George W. LeMaitre (150,000 shares on Feb 26 and 55,930 on Mar 2), a director sale and an officer sale — totaling roughly ~215k shares disclosed across filings; this could create short‑term selling pressure or raise governance/insider‑confidence questions for some investors. Read More.

Hedge Funds Weigh In On LeMaitre Vascular

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Mercer Global Advisors Inc. ADV lifted its position in shares of LeMaitre Vascular by 11.5% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 3,606 shares of the medical instruments supplier’s stock valued at $292,000 after buying an additional 371 shares during the last quarter. NewEdge Advisors LLC raised its stake in shares of LeMaitre Vascular by 4.6% during the 4th quarter. NewEdge Advisors LLC now owns 3,158 shares of the medical instruments supplier’s stock worth $256,000 after acquiring an additional 139 shares in the last quarter. Empowered Funds LLC purchased a new stake in LeMaitre Vascular during the fourth quarter valued at approximately $289,000. nVerses Capital LLC acquired a new stake in LeMaitre Vascular in the fourth quarter valued at approximately $234,000. Finally, Voloridge Investment Management LLC boosted its stake in LeMaitre Vascular by 70.0% in the fourth quarter. Voloridge Investment Management LLC now owns 62,909 shares of the medical instruments supplier’s stock valued at $5,102,000 after acquiring an additional 25,901 shares in the last quarter. Hedge funds and other institutional investors own 84.64% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on LMAT. Citizens Jmp upped their target price on shares of LeMaitre Vascular from $113.00 to $118.00 and gave the stock a “market outperform” rating in a research note on Thursday, February 26th. Wall Street Zen raised LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Zacks Research lowered LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research report on Thursday, January 1st. Wells Fargo & Company increased their price target on LeMaitre Vascular from $87.00 to $94.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 26th. Finally, Barrington Research lifted their price objective on LeMaitre Vascular from $95.00 to $105.00 and gave the company an “outperform” rating in a report on Thursday, February 26th. Three investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $105.80.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.